Hematopoietic stem cell transplantation for thalassemia

Area of Science:

• Hematology
• Genetics
• Pediatrics

Background:

• Thalassemia is an inherited blood disorder causing reduced hemoglobin synthesis.
• Beta-thalassemia major necessitates lifelong treatment with transfusions or stem cell transplantation.
• Current treatments carry risks like infection and iron overload.

Purpose of the Study:

• To review therapeutic options for beta-thalassemia major.
• To highlight the efficacy and risks of current treatments.
• To discuss emerging strategies for managing high-risk patients.

Main Methods:

• Review of existing literature on thalassemia treatments.
• Analysis of outcomes for transfusion therapy and stem cell transplant.
• Examination of novel pre-transplant conditioning regimens and future therapies.

Main Results:

• Allogeneic stem cell transplant is the only curative option for beta-thalassemia major.
• Outcomes for stem cell transplant are excellent in low-risk patients (over 90% transfusion-free).
• High-risk patients may benefit from intensified pre-transplant therapies to reduce graft rejection.

Conclusions:

• Stem cell transplant offers a definitive cure for beta-thalassemia major, especially in low-risk individuals.
• Management of high-risk patients is improving with new conditioning strategies.
• Gene therapy and unrelated donor transplants are promising future directions.